Skip to main content
. Author manuscript; available in PMC: 2022 Dec 28.
Published in final edited form as: Invest New Drugs. 2022 Oct 20;40(6):1306–1314. doi: 10.1007/s10637-022-01311-w

Table 3.

Reasons Off Treatment by Total Number of Treatment Cycles Given

Off Treatment Reason Total Number of Cycles Given
1 2 3 4 6 10 Total
N N N N N N N %
Adverse event/side effects/complications 1 1 1 0 0 0 3 25.0
Death on study 0 1 0 0 0 0 1 8.3
Disease progression- relapse during active treatment 0 0 0 1 1 2 4 33.3
Patient withdrawal/refusal after beginning protocol therapy 0 0 1 1 0 0 2 16.7
Other 1a 0 1b 0 0 0 2 16.7
Total 2 2 3 2 1 2 12 100.0
a

Off treatment for medical decision

b

off treatment due to symptoms demonstrating disease progression and/or intolerance of sapanisertib